Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:36:54.285Z.
Calculation as of: 2026-10-06T20:36:54.285Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 12822cf5764c24a0ef00c724f2a960962c8ab94682162e48d6be38065653aaef
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$10.13B
Price/FCF Ratio
N/A
TTM Avg
33.51
3Y Avg
42.70
5Y Avg
52.87
Market Cap
$10.19B
Price/FCF Ratio
37.87
TTM Avg
38.11
3Y Avg
56.02
5Y Avg
36.47
Market Cap
$10.03B
Price/FCF Ratio
23.93
TTM Avg
30.62
3Y Avg
33.44
5Y Avg
29.54
Market Cap
$10.31B
Price/FCF Ratio
13.73
TTM Avg
18.91
3Y Avg
32.94
5Y Avg
37.10
Market Cap
$9.93B
Price/FCF Ratio
28.12
TTM Avg
23.67
3Y Avg
33.34
5Y Avg
46.70
Market Cap
$10.40B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$9.87B
Price/FCF Ratio
89.08
TTM Avg
79.40
3Y Avg
81.24
5Y Avg
180.79
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | $10.15B | N/A | N/A | N/A | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.13B | N/A | 33.51 | 42.70 | 52.87 |
| Molina Healthcare, Inc. (MOH)vs › | $10.19B | 37.87 | 38.11 | 56.02 | 36.47 |
| 10x Genomics, Inc. (TXG)vs › | $10.24B | 84.33 | 36.22 | 40.76 | 40.76 |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 23.93 | 30.62 | 33.44 | 29.54 |
| Globus Medical, Inc. (GMED)vs › | $10.31B | 13.73 | 18.91 | 32.94 | 37.10 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 28.12 | 23.67 | 33.34 | 46.70 |
| Twist Bioscience Corporation (TWST)vs › | $10.40B | N/A | N/A | N/A | N/A |
| Repligen Corporation (RGEN)vs › | $9.87B | 89.08 | 79.40 | 81.24 | 180.79 |
| Henry Schein, Inc. (HSIC)vs › | $9.66B | 17.93 | 20.79 | 20.36 | 19.71 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
